TY - JOUR
T1 - Magnetic Resonance Spectroscopy
T2 - An in Vivo Molecular Imaging Biomarker for Parkinson's Disease?
AU - Ciurleo, Rosella
AU - Di Lorenzo, Giuseppe
AU - Bramanti, Placido
AU - Marino, Silvia
PY - 2014
Y1 - 2014
N2 - Parkinson's disease (PD) is a neurodegenerative disorder caused by selective loss of dopaminergic neurons in the substantia nigra pars compacta which leads to dysfunction of cerebral pathways critical for the control of movements. The diagnosis of PD is based on motor symptoms, such as bradykinesia, akinesia, muscular rigidity, postural instability, and resting tremor, which are evident only after the degeneration of a significant number of dopaminergic neurons. Currently, a marker for early diagnosis of PD is still not available. Consequently, also the development of disease-modifying therapies is a challenge. Magnetic resonance spectroscopy is a quantitative imaging technique that allows in vivo measurement of certain neurometabolites and may produce biomarkers that reflect metabolic dysfunctions and irreversible neuronal damage. This review summarizes the abnormalities of cerebral metabolites found in MRS studies performed in patients with PD and other forms of parkinsonism. In addition, we discuss the potential role of MRS as in vivo molecular imaging biomarker for early diagnosis of PD and for monitoring the efficacy of therapeutic interventions.
AB - Parkinson's disease (PD) is a neurodegenerative disorder caused by selective loss of dopaminergic neurons in the substantia nigra pars compacta which leads to dysfunction of cerebral pathways critical for the control of movements. The diagnosis of PD is based on motor symptoms, such as bradykinesia, akinesia, muscular rigidity, postural instability, and resting tremor, which are evident only after the degeneration of a significant number of dopaminergic neurons. Currently, a marker for early diagnosis of PD is still not available. Consequently, also the development of disease-modifying therapies is a challenge. Magnetic resonance spectroscopy is a quantitative imaging technique that allows in vivo measurement of certain neurometabolites and may produce biomarkers that reflect metabolic dysfunctions and irreversible neuronal damage. This review summarizes the abnormalities of cerebral metabolites found in MRS studies performed in patients with PD and other forms of parkinsonism. In addition, we discuss the potential role of MRS as in vivo molecular imaging biomarker for early diagnosis of PD and for monitoring the efficacy of therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=84930913224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930913224&partnerID=8YFLogxK
U2 - 10.1155/2014/519816
DO - 10.1155/2014/519816
M3 - Article
C2 - 25302300
AN - SCOPUS:84930913224
VL - 2014
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 519816
ER -